Experimental Oncology, 2010, № 1

International conference “Tumor and host: novel aspects of old problem” 21–24 September 2010 Кyiv, Ukraine

Fri, 01 Jan 2010 00:00:00 GMT

International conference “Tumor and host: novel aspects of old problem” 21–24 September 2010 Кyiv, Ukraine 21-24 September 2010 Кyiv, Ukraine

Administration of vitamin D3 improves antimetastatic efficacy of cancer vaccine therapy of Lewis lung carcinoma

Fri, 01 Jan 2010 00:00:00 GMT

Administration of vitamin D3 improves antimetastatic efficacy of cancer vaccine therapy of Lewis lung carcinoma Zhuravel, E.; Efanova, O.; Shestakova, T.; Glushko, N.; Mezhuev, O.; Soldatkina, M.; Pogrebnoy, P.V. Aim: To analyze antitumor efficacy of experimental cancer vaccine therapy combined with introduction of vitamin D3 (VD3) for treatment of Lewis lung carcinoma (3LL). Materials and Methods: Cancer vaccines composed from recombinant murine beta-defensin-2 (mBD-2) and 3LL cell lysate, or DNA, coding for mBD-2-Muc1 fusion construct cloned in pcDNA3+ vector, were prepared and used for intradermal vaccination. Experimental cancer vaccines introduced i. d. at therapeutic and prophylactic regimens to 3LLbearing C57Bl mice, were applied alone or in combination with VD3 (administered per os) and/or low-dose cyclophosphamide (CP, administered intraperitoneal). Efficacy of treatments was analyzed by primary tumor growth dynamics indexes and by metastasis rate in vaccinated animals. Results: As it has been shown, administration of the protein-based vaccine composed from mBD-2 and 3LL cell lysate in combination with VD3 and CP, but not in VD3 free setting, led to significant suppression of primary tumor growth (p < 0.005) and had significant antimetastatic effect. Introduction of VD3 with or without CP in the scheme of treatment with mBD-2-Muc1-DNA vaccine at therapeutic regimen has led to significant suppression of primary tumor (p < 0.05) and metastasis volumes (p < 0.005), while in the groups of animals treated with DNA-vaccine + VD3 with or without CP at prophylactic regimen, significant antimetastatic effect (p < 0.05) and elevation of average life-span (p < 0.05) have been registered. Conclusion: The results of this pilot study have shown promising clinical effects of VD3 administration in combination with cancer vaccinotherapy in vivo.

Hyperthermic effect of multi-walled carbon nanotubes stimulated with near infrared irradiation for anticancer therapy: in vitro studies

Fri, 01 Jan 2010 00:00:00 GMT

Hyperthermic effect of multi-walled carbon nanotubes stimulated with near infrared irradiation for anticancer therapy: in vitro studies Burlaka, A.; Lukin, S.; Prylutska, S.; Remeniak, O.; Prylutskyy, Yu.; Shuba, M.; Maksimenko, S.; Ritter, U.; Scharff, P. It is proposed to use the novel paradigm of treating cancer with hyperthermic therapy using multi-walled carbon nanotubes (MWCNT) stimulated with near infrared (NIR) irradiation. Aim: To establish the capacity of MWCNT stimulated with NIR irradiation to destroy Erlich ascitic carcinoma (EAC) cells. Materials and Methods: EAC cells suspension was irradiated with NIR heating lamp with a wavelength of 0.78–1.40 mm and power density of 3.5 W/cm2 over 1.5 min in the presence of MWCNT (0.1 mg/ml). The changes in the temperature of suspension with the NIR exposure time was measured using the differential cooper-constantan thermocouple. The viability of EAC cells was evaluated by trypan blue staining. Results: The death of 95.2% of EAC cells in the presence of MWCNT was observed after 1.5 min of NIR light irradiation: thermal ablation temperature was ~50 °C. Conclusions: It was demonstrated that addition of MWCNT to EAC cell suspension results in the photo-ablative destruction of cells exposed to short time NIR irradiation.

No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients

Fri, 01 Jan 2010 00:00:00 GMT

No significant association between the promoter region polymorphisms of factor VII gene and risk of venous thrombosis in cancer patients Eroglu, A.; Ozturk, A.; Cam, R.; Akar, N. Factor VII (FVII) plays an important role in blood coagulation. The role of common polymorphisms influencing the FVII plasma levels in thromboembolic disorders has been evaluated but there is no published data related to the effect of FVII gene polymorphisms on the venous thrombosis risk in cancer. Aim: To investigate the association of three common functional polymorphisms in the promoter region of FVII gene: a decanucleotide insertion at position-323 (-323ins10-bp), a G to T substitution at position-401 (-401GT), and a G to A substitution at position-402 (-401GT) with venous thrombosis in cancer patients. Materials and Methods: The study included 60 cancer patients with venous thromboembolism (VTE) (group 1) and 130 cancer patients without VTE (group 2). Genotyping of -323ins10-bp, -401GT, and -402GA polymorphisms in the promoter region of FVII gene was performed by the method of single-strand conformation polymorphism analysis and sequencing. Factor V Leiden (FVL) was also determined in all cases. Results: The frequency of FVL was significantly greater in cancer patients with VTE compared with group 2 patients (p < 0.0001). For each polymorphism of FVII gene, the distributions of genotypes and allele frequencies were not significantly different between two groups of patients (p > 0.05). The results did not change significantly after the exclusion of patients carrying the FVL (p > 0.05). Conclusions: The screening for the -323ins10-bp, -401GT, and -402GA olymorphisms of FVII gene did not contribute to a meaningful diagnostic nvestigation in cancer patients with venous thrombosis.